Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELEN-008: Capecitabine + Endocrine Therapy in HR+/HER2- Breast Cancer
NCT05063136Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Henan Cancer Hospital. Started Sep 2021; status: recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05063136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063136.